Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(4.21)
# 1,444
Out of 4,534 analysts
78
Total ratings
46.3%
Success rate
17.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATAI AtaiBeckley | Downgraded: Hold | n/a | $7.19 | - | 1 | Jul 16, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $100 | $36.99 | +170.34% | 11 | Jul 7, 2026 | |
| PMN ProMIS Neurosciences | Initiated Coverage: Buy | $40 | $15.08 | +163.68% | 1 | Jun 29, 2026 | |
| AXSM Axsome Therapeutics | Maintained: Buy | $220 → $272 | $221.64 | +22.72% | 5 | May 4, 2026 | |
| ALEC Alector | Upgraded: Buy | n/a | $1.43 | - | 3 | Apr 15, 2026 | |
| RZLT Rezolute | Maintained: Hold | n/a | $4.45 | - | 6 | Mar 25, 2026 | |
| ALKS Alkermes | Maintained: Buy | $43 | $51.72 | -16.86% | 1 | Mar 11, 2026 | |
| NVAX Novavax | Maintained: Buy | $18 | $7.88 | +128.43% | 2 | Jan 13, 2026 | |
| CRVO CervoMed | Initiated Coverage: Buy | n/a | $2.79 | - | 1 | Dec 18, 2025 | |
| HELP Cybin | Reiterated: Buy | n/a | $7.11 | - | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $101.00 | - | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.86 | n/a | 5 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.8141 | n/a | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $74.61 | n/a | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.97 | n/a | 7 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.57 | n/a | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $1.07 | n/a | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $3.05 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $5.75 | n/a | 4 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $2.21 | n/a | 3 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $22.16 | n/a | 3 | Jun 23, 2023 |
AtaiBeckley
Jul 16, 2026
Downgraded: Hold
Price Target: n/a
Current: $7.19
Upside: -
Vera Therapeutics
Jul 7, 2026
Maintained: Buy
Price Target: $100
Current: $36.99
Upside: +170.34%
ProMIS Neurosciences
Jun 29, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $15.08
Upside: +163.68%
Axsome Therapeutics
May 4, 2026
Maintained: Buy
Price Target: $220 → $272
Current: $221.64
Upside: +22.72%
Alector
Apr 15, 2026
Upgraded: Buy
Price Target: n/a
Current: $1.43
Upside: -
Rezolute
Mar 25, 2026
Maintained: Hold
Price Target: n/a
Current: $4.45
Upside: -
Alkermes
Mar 11, 2026
Maintained: Buy
Price Target: $43
Current: $51.72
Upside: -16.86%
Novavax
Jan 13, 2026
Maintained: Buy
Price Target: $18
Current: $7.88
Upside: +128.43%
CervoMed
Dec 18, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $2.79
Upside: -
Cybin
Oct 15, 2025
Reiterated: Buy
Price Target: n/a
Current: $7.11
Upside: -
Aug 22, 2025
Reiterated: Buy
Price Target: n/a
Current: $101.00
Upside: -
Jul 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.86
Upside: n/a
Jul 7, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.8141
Upside: n/a
Jul 2, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $74.61
Upside: n/a
Jul 1, 2025
Reiterated: Buy
Price Target: n/a
Current: $5.97
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $5.57
Upside: n/a
Mar 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $1.07
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $3.05
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $34
Current: $5.75
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $13
Current: $2.21
Upside: n/a
Jun 23, 2023
Rated: Hold
Price Target: n/a
Current: $22.16
Upside: n/a